In February 2018, Aratana announced an animal health research and development collaboration with AskAt Inc. The collaboration includes an option agreement for multiple therapeutic candidates with potential in pain, allergy and cancer, as well as exclusive, worldwide rights to develop and commercialize AT-019, a potent and innovative EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation and other indications.
The rest of the voluminous report looks good to me but this holds particular interest for me and perhaps for Aratana's near future.
Notice the "potent and innovative EP4 receptor antagonist therapeutic candidate" above in the Japanese collaboration and then look at mention in this description of Galliprant that PETX brought through FDA licensing:
It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation
- I don't know what it means exactly but blocking that EP4 receptor in dogs relieves the pain and inflammation of osteoarthritis while not preventing the natural lubrication of joints like NSAIDS.
Then going way beyond:
the very recent 3D modeling of the human EP4 receptor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.